- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00703911
Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors (ONE)
22. November 2016 aktualisiert von: Novo Nordisk A/S
A Prospective Observational Registry on the Use of NovoSeven® (Activated Recombinant Human Factor VIIa) for on Demand Treatment of Mild to Moderate Bleeds in Haemophilia A and B Patients With Inhibitors
This study was conducted in Africa, Europe, the Middle-East and South America.
The primary objective of this registry was to observe the use of single dose and multi-dose use of activated recombinant human factor VII and to compare short-term outcomes, including effectiveness, safety, quality of life and treatment satisfaction with the approved treatments.
Studienübersicht
Status
Abgeschlossen
Intervention / Behandlung
Studientyp
Beobachtungs
Einschreibung (Tatsächlich)
102
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Algiers, Algerien, 16035
- Novo Nordisk Investigational Site
-
-
-
-
-
Brussels, Belgien, 1070
- Novo Nordisk Investigational Site
-
-
-
-
-
Mainz, Deutschland, 55127
- Novo Nordisk Investigational Site
-
-
-
-
-
Paris La défense cedex, Frankreich, 92932
- Novo Nordisk Investigational Site
-
-
-
-
-
Rome, Italien, 00144
- Novo Nordisk Investigational Site
-
-
-
-
-
Alphen a/d Rijn, Niederlande
- Novo Nordisk Investigational Site
-
-
-
-
-
Warszawa, Polen, PL-02-274
- Novo Nordisk Investigational Site
-
-
-
-
-
Paco de Arcos, Portugal, 2780-730
- Novo Nordisk Investigational Site
-
-
-
-
-
Riyadh, Saudi-Arabien, 3542
- Novo Nordisk Investigational Site
-
-
-
-
-
Malmö, Schweden, 202 15
- Novo Nordisk Investigational Site
-
-
-
-
-
Sandton, Südafrika, 2146
- Novo Nordisk Investigational Site
-
-
-
-
-
Istanbul, Truthahn, 34335
- Novo Nordisk Investigational Site
-
-
-
-
-
Prague, Tschechische Republik, 16000
- Novo Nordisk Investigational Site
-
-
-
-
-
Caracas, Venezuela
- Novo Nordisk Investigational Site
-
-
-
-
-
Crawley, Vereinigtes Königreich, RH11 9RT
- Novo Nordisk Investigational Site
-
-
-
-
-
Vienna, Österreich, A-1010
- Novo Nordisk Investigational Site
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Männlich
Probenahmeverfahren
Nicht-Wahrscheinlichkeitsprobe
Studienpopulation
Patients with haemophilia A or B with inhibitors, using activated recombinant human factor VII as on-demand treatment
Beschreibung
Inclusion Criteria:
- Diagnosed with haemophilia A or B with inhibitors
- Experience mild to moderate spontaneous bleeds which require on-demand treatment and who are currently prescribed activated recombinant human factor VII
- Be able and willing to provide informed consent (or proxy consent by caregiver, if applicable), as required by local research ethics committee, governmental or regulatory authorities
- Be willing to provide information on at least one alternate contact person in the event that the patient be somehow lost-to-follow-up over the course of registry participation (not applicable if patient is withdrawn)
Exclusion Criteria:
- Known hypersensitivity to the active substance or the excipients in the formulation of activated recombinant human factor VII, or to mouse, hamster or bovine protein
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
activated recombinant human factor VII
Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds
|
Treatment of patients experiencing bleeds at the discretion of the physician/caregiver
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (All Bleed Episodes)
Zeitfenster: within 9 hours of first injection
|
The percentage of bleed treatments successfully resulting in bleed resolution.
Analysis only considers the patient's opinion of effectiveness at 9 hours, with a rating of "Effective" considered as successful treatment.
|
within 9 hours of first injection
|
Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (Spontaneous Bleed Episodes)
Zeitfenster: within 9 hours of first injection
|
The percentage of bleed treatments successfully resulting in bleed resolution.
Analysis only considers the patient's opinion of effectiveness at 9 hours, with a rating of "Effective" considered as successful treatment.
|
within 9 hours of first injection
|
Percentage of Bleed Treatments Resulting in Effective Pain Relief (All Bleed Episodes)
Zeitfenster: within 9 hours of first injection
|
The percentage of participants with effective pain relief.
Pain relief was a subjective assessment made by the patient during treatment of a bleed episode.
|
within 9 hours of first injection
|
Percentage of Bleed Treatments Resulting in Effective Pain Relief (Spontaneous Bleed Episodes)
Zeitfenster: within 9 hours of first injection
|
The percentage of participants with effective pain relief.
Pain relief was a subjective assessment made by the patient during treatment of a bleed episode.
|
within 9 hours of first injection
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleeds) by Time Point (All Bleed Episodes)
Zeitfenster: 1 hour, 3 hours and 6 hours, respectively, after first injection
|
Effective haemostasis at 3 different time points for all bleeds.
Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.
|
1 hour, 3 hours and 6 hours, respectively, after first injection
|
Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleeds) by Time Point (Spontaneous Bleed Episodes)
Zeitfenster: 1 hour, 3 hours and 6 hours, respectively, after first injection
|
Effective haemostasis at 3 different time points for all bleeds.
Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.
|
1 hour, 3 hours and 6 hours, respectively, after first injection
|
Percentage of Bleed Treatments Resulting in Effective Pain Relief by Time Point (All Bleed Episodes)
Zeitfenster: 1 hour, 3 hours and 6 hours, respectively, after first injection
|
Effective pain relief at 3 different time points for all bleeds.
Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.
|
1 hour, 3 hours and 6 hours, respectively, after first injection
|
Percentage of Bleed Treatments Resulting in Effective Pain Relief by Time Point (Spontaneous Bleed Episodes)
Zeitfenster: 1 hour, 3 hours and 6 hours, respectively, after first injection
|
Effective pain relief at 3 different time points for spontaneous bleeds.
Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.
|
1 hour, 3 hours and 6 hours, respectively, after first injection
|
Total Number of Injections (All Bleed Episodes)
Zeitfenster: individual bleed episode
|
The median number of injections required to treat individual bleed episodes.
|
individual bleed episode
|
Total Number of Injections (Spontaneous Bleed Episodes)
Zeitfenster: individual bleed episode
|
The median number of injections required to treat individual bleed episodes.
|
individual bleed episode
|
Total Exposure (Cumulative Dose) to Activated Recombinant Human Factor VII (All Bleed Episodes)
Zeitfenster: individual bleed episode
|
The median total cumulative dose required to treat individual bleed episodes.
|
individual bleed episode
|
Total Exposure (Cumulative Dose) to Activated Recombinant Human Factor VII (Spontaneous Bleed Episodes)
Zeitfenster: individual bleed episode
|
The median total cumulative dose required to treat individual bleed episodes.
|
individual bleed episode
|
Percentage of Patients Reporting Satisfaction With Symptom Relief (All Bleed Episodes)
Zeitfenster: duration of bleed episode
|
Patient rate of satisfaction with symptom relief for the bleed episode overall on a 7-point Likert scale.
Completion of questionnaire was voluntary.
A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured.
Scale answers ranged from extremely satisfied to extremely dissatisfied.
The percentage of bleed episodes for which patients reported "extremely satisfied", "very satisfied" or "satisfied" is presented.
|
duration of bleed episode
|
Percentage of Bleed Treatments Resulting in Patient Satisfaction With Symptom Relief (Spontaneous Bleed Episodes)
Zeitfenster: duration of bleed episode
|
Patient rate of satisfaction with symptom relief for the bleed episode overall on a 7-point Likert scale.
Completion of questionnaire was voluntary.
A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured.
Scale answers ranged from extremely satisfied to extremely dissatisfied.
The percentage of bleed episodes for which patients reported "extremely satisfied", "very satisfied" or "satisfied" is presented.
|
duration of bleed episode
|
Percentage of Bleed Treatments Resulting in Patient Satisfaction With Ease of Use (All Bleed Episodes)
Zeitfenster: duration of bleed episode
|
Rate of ease of use related to activated recombinant human factor VII on a 7-point Likert scale.
Completion of questionnaire was voluntary.
A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured.
Scale answers ranged from extremely difficult to extremely easy.
The percentage of bleed episodes for which patients reported "extremely easy", "very easy" or "easy" is presented.
|
duration of bleed episode
|
Percentage of Bleed Treatments Resulting in Patient Satisfaction With Ease of Use (Spontaneous Bleed Episodes)
Zeitfenster: duration of bleed episode
|
Rate of ease of use related to activated recombinant human factor VII on a 7-point Likert scale.
Completion of questionnaire was voluntary.
A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured.
Scale answers ranged from extremely difficult to extremely easy.
The percentage of bleed episodes for which patients reported "extremely easy", "very easy" or "easy" is presented.
|
duration of bleed episode
|
Overall Time to Cessation of Bleed/Achievement of Haemostasis (All Bleed Episodes)
Zeitfenster: duration of bleed episode
|
Median time to achievement of haemostasis/bleed cessation calculated using Kaplan Meier life table methods.
If approximately 50% or less of bleeds achieved the endpoint in a given initial dose subgroup, the median cannot be calculated and it is reported as not applicable
|
duration of bleed episode
|
Overall Time to Cessation of Bleed/Achievement of Haemostasis (Spontaneous Bleed Episodes)
Zeitfenster: duration of bleed episode
|
Median time to achievement of haemostasis/bleed cessation calculated using Kaplan Meier life table methods.
If approximately 50% or less of bleeds achieved the endpoint in a given initial dose subgroup, the median cannot be calculated and it is reported as not applicable
|
duration of bleed episode
|
Overall Time to Cessation/Achievement of Haemostasis (Spontaneous Bleed Episodes)
Zeitfenster: duration of bleed episode
|
Median time to achievement of haemostasis/bleed cessation calculated using Kaplan Meier life table methods.
If approximately 50% or less of bleeds achieved the endpoint in a given initial dose subgroup, the median cannot be calculated and it is reported as not applicable.
|
duration of bleed episode
|
Childrens' Health Related Quality of Life (Haemo-QoL): Overall Score
Zeitfenster: Baseline (week 0) and and registry discontinuation (up to 28 months)
|
The Haemo-QoL is a specific multidimensional validated and reliable questionnaire used to assess quality of life in patients with haemophilia.
Scores are reported on a 0 to 100 scale-higher scores indicate more impairment.
|
Baseline (week 0) and and registry discontinuation (up to 28 months)
|
Adults' Health Related Quality of Life (Haemo-QoL-A): Overall Score
Zeitfenster: Baseline (week 0) and and registry discontinuation (up to 28 months)
|
The adult Haemo-QoL-A is a specific multidimensional validated and reliable questionnaire used to assess quality of life in patients with haemophilia.
Scores are reported on a 0 to 100 scale-higher scores indicate more impairment.
|
Baseline (week 0) and and registry discontinuation (up to 28 months)
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleed) by Dose Level (All Bleed Episodes)
Zeitfenster: within 9 hours after first injection
|
Percentage of bleeds with effective haemostasis within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: "effective" = bleed resolved or substantially improved; "partially effective" = bleed with some improvement; "ineffective" = bleed with no change or with worsening.
|
within 9 hours after first injection
|
Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleed) by Dose Level (Spontaneous Bleed Episodes)
Zeitfenster: within 9 hours after first injection
|
Percentage of bleeds with effective haemostasis within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: "effective" = bleed resolved or substantially improved; "partially effective" = bleed with some improvement; "ineffective" = bleed with no change or with worsening.
|
within 9 hours after first injection
|
Percentage of Bleed Treatments Resulting in Effective Pain Relief by Initial Dose (All Bleed Episodes)
Zeitfenster: within 9 hours after first injection
|
Percentage of bleeds with effective pain relief within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: "Better" = pain resolved or decreased substantially; "Same" = no change; "Worsened" = pain worsening.
|
within 9 hours after first injection
|
Percentage of Bleed Treatments Resulting in Effective Pain Relief by Initial Dose (Spontaneous Bleed Episodes)
Zeitfenster: within 9 hours after first injection
|
Percentage of bleeds with effective pain relief within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: "Better" = pain resolved or decreased substantially; "Same" = no change; "Worsened" = pain worsening.
|
within 9 hours after first injection
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Nützliche Links
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. März 2008
Primärer Abschluss (Tatsächlich)
1. Juli 2010
Studienabschluss (Tatsächlich)
1. Juli 2010
Studienanmeldedaten
Zuerst eingereicht
19. Juni 2008
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
23. Juni 2008
Zuerst gepostet (Schätzen)
24. Juni 2008
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
11. Januar 2017
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
22. November 2016
Zuletzt verifiziert
1. November 2016
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- F7HAEM-3507
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Angeborene Blutungsstörung
-
Universitätsmedizin MannheimAbgeschlossenPerkutane Koronarintervention (PCI) | Arterielle Verschlussvorrichtung | Greifen Sie auf Site Bleeding zu | Unerwünschte kardiale EreignisseDeutschland
-
Children's Hospital Medical Center, CincinnatiEunice Kennedy Shriver National Institute of Child Health and Human Development... und andere MitarbeiterRekrutierungÖsophagusatresie | Tracheoösophageale Fistel | Trachealstenose | Kehlkopfspalte | Bronchialstenose | Ösophagusbronchus | Congenital High Airway Obstruction SyndromeVereinigte Staaten
-
National Human Genome Research Institute (NHGRI)RekrutierungStoffwechselkrankheit | Purin-Pyrimidin-Stoffwechsel | AICDA, OMIM *605257, Immunschwäche mit Hyper-IgM, Typ 2; HIGM2 | UNG, OMIM *191525, Hyper-IgM-Syndrom 5 | NT5C3A, OMIM *606224, Anämie, hämolytisch, aufgrund von UMPH1-Mangel | UMPS, OMIM *613891, Orotische Azidurie | DHODH, OMIM *126064... und andere BedingungenVereinigte Staaten
Klinische Studien zur eptacog alfa (activated)
-
Novo Nordisk A/SAbgeschlossenAngeborene Blutungsstörung | Hämophilie A mit Inhibitoren | Hämophilie B mit InhibitorenVereinigte Staaten
-
Novo Nordisk A/SAbgeschlossenSchwere postpartale BlutungSchweiz
-
Novo Nordisk A/SAbgeschlossenAngeborene Blutungsstörung | Hämophilie A | Hämophilie BVereinigte Staaten, Spanien, Taiwan, Truthahn, Polen, Kroatien, Italien, Malaysia, Brasilien, Vereinigtes Königreich, Ungarn, Israel, Thailand, Japan, Südafrika, Kanada, Frankreich, Argentinien
-
AryoGen Pharmed Co.AbgeschlossenFaktor-VII-MangelIran, Islamische Republik
-
AryoGen Pharmed Co.AbgeschlossenHämophilie A mit Inhibitor | Hämophilie B mit InhibitorIran, Islamische Republik
-
Novo Nordisk A/SAbgeschlossenErworbene Blutungsstörung | Intrazerebrale BlutungVereinigte Staaten, Spanien, Deutschland, Schweden, Niederlande, Österreich, Belgien, Singapur, Taiwan, Israel, Italien, Dänemark, Australien, Thailand, Frankreich, Norwegen, Kroatien, Hongkong, China, Kanada, Schweiz, Brasilien, Fi...
-
Novo Nordisk A/SAbgeschlossenAngeborene Blutungsstörung | Hämophilie A mit Inhibitoren | Hämophilie B mit InhibitorenTaiwan, Vereinigtes Königreich, Thailand, Serbien, Kroatien, Italien, Polen, Rumänien, Ungarn, Malaysia, Vereinigte Staaten, Österreich, Brasilien, Griechenland, Japan, Puerto Rico, Russische Föderation, Südafrika, Truthahn
-
AryoGen Pharmed Co.AbgeschlossenHämophilie A oder B mit InhibitorIran, Islamische Republik, Truthahn
-
Novo Nordisk A/SBeendetTrauma | Erworbene BlutungsstörungSpanien, Hongkong, Deutschland, Frankreich, Vereinigtes Königreich, Brasilien, Italien, Ungarn, Niederlande, Vereinigte Staaten, Schweiz, Tschechische Republik, Griechenland, Südafrika
-
CSL BehringAbgeschlossenAngeborener Gerinnungsfaktor-VII-MangelNiederlande, Norwegen